Tesamorelin vs CJC-1295 — GHRH analogues compared
Tesamorelin and CJC-1295 are both modified GHRH(1-29) analogues — they share a common parent peptide and target the same GHRH receptor — but differ in modifications and half-life. Tesamorelin is the FDA-approved version (since 2010 for HIV-associated lipodystrophy) with a half-life of ~26-38 minutes. CJC-1295 with DAC (drug affinity complex) carries an additional maleimide group that covalently binds serum albumin, extending the half-life to ~6-8 days — meaning a single weekly dose maintains GHRH receptor activity. CJC-1295 without DAC has a half-life similar to tesamorelin. Both compounds preserve pulsatile GH release rather than producing supraphysiologic GH spikes.
Side-by-side
| Tesamorelin 10 mg | CJC-1295 (with or without DAC) | |
|---|---|---|
| Receptor | GHRH receptor | GHRH receptor (same) |
| Modifications | N-terminal trans-3-hexenoyl group | D-Ala²-Gln⁸-Ala¹⁵-Leu²⁷ (+ DAC version: maleimide) |
| Half-life | ~26–38 minutes | No-DAC: ~30 min · DAC: ~6-8 days |
| Approval | FDA approved 2010 (Egrifta) | Not approved — research only |
| Approved indication | HIV-associated lipodystrophy | None |
| Dosing in research | Daily SC | No-DAC: 1-2× daily · DAC: 1-2× weekly |
| Originator | Theratechnologies | ConjuChem |
What to know
- ·Both produce pulsatile GH release rather than overriding the natural pulsatility — this is the mechanistic appeal of GHRH analogues over direct rhGH administration.
- ·Tesamorelin has the larger evidence base — phase 3 trials, 16-year approved track record, and ongoing research in non-HIV visceral-fat indications.
- ·CJC-1295 with DAC has the longer half-life but human clinical development was abandoned by ConjuChem in 2007 (for funding/strategic reasons, not safety) — research literature is therefore limited to early trials and animal models.
- ·Both raise IGF-1 in trial subjects; tesamorelin trial data shows ~80–100 ng/mL IGF-1 increase over baseline.
- ·Both are research-use only on this catalogue.
Where the literature diverges
Tesamorelin literature is clinically mature — TIRRA and TIROS trials in HIV lipodystrophy, plus follow-on research in cognitive endpoints (Alzheimer's pilot studies), NAFLD, and visceral adiposity. CJC-1295 literature is dominated by animal-model and early human PK/PD studies, with limited clinical-endpoint data due to abandoned development. Researchers choosing between them typically choose tesamorelin for clinical question rigour, CJC-1295 for extended dosing intervals in animal-model work.
FAQ
Which one is "stronger"?+
Both bind the same GHRH receptor with similar affinity. Functionally, CJC-1295 with DAC produces sustained continuous receptor activation (because the long half-life keeps drug levels above EC50), while tesamorelin produces pulsatile activation (because clearance allows trough). The 'sustained' pattern of DAC-CJC-1295 is debated in the literature — some argue it disrupts natural pulsatility, others argue continuous activation is functionally equivalent.
Why is CJC-1295 not approved?+
Development by ConjuChem was abandoned in 2007 for strategic/funding reasons — the company restructured away from the GHRH program. The compound never received the focused phase 3 investment needed for regulatory submission. Tesamorelin proceeded through phase 3 under Theratechnologies and was approved.
Are they paired with ipamorelin in research?+
Common research-protocol pairing: a GHRH analogue (tesamorelin or CJC-1295) + a GHS receptor agonist (ipamorelin or sermorelin). The two receptor systems produce additive GH release in animal models. This is research-context, not a recommendation for self-administration.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchTesamorelin 10 mg
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
- ResearchCJC-1295 with DAC 5 mg
CJC-1295 with Drug Affinity Complex (DAC) — an extended GHRH analogue designed for half-life extension through covalent albumin binding.
- ResearchCJC-1295 no DAC 10 mg
CJC-1295 without DAC — short-acting modified GRF(1-29). Commonly used in preclinical GH-pulse research alongside ipamorelin.
- GlossaryGHRH
Growth hormone-releasing hormone, the hypothalamic peptide that triggers GH release.
- BiomarkerTSH 4.5 mIU/L
TSH at 4.5 mIU/L sits at the top edge of most printed reference ranges (typically 0.4–4.0). What that number indicates physiologically, why "high-normal" matters, and what the research literature looks at when this pattern appears.
- BiomarkerFree T3 low, TSH normal
Free T3 below the reference range with a normal TSH suggests your body isn't converting T4 into the active T3 hormone efficiently. The research literature on conversion problems and what they look like.